A specific claim received a direct test
A twelve-week randomized, blinded trial assigned 40 men with obesity and insulin resistance, without diabetes, to NR or placebo. Researchers performed oral glucose-tolerance tests and measured glucose, insulin, C-peptide, glucagon, GLP-1 and GIP. NR did not change the measured fasting or post-challenge hormone concentrations or calculated beta-cell function. [1]
Circulating bile acids and adipsin also did not change. The report does not support a claim that NR improved incretin secretion or glucose tolerance in this population. It is a focused human test of a mechanism suggested by earlier preclinical research. [1]
A familiar hormone name is not a treatment category
GLP-1 can appear in many different conversations, including physiology, medicines and supplement marketing. The presence of the term in a paper does not make the tested supplement equivalent to a medicine that acts on a related pathway. Read what was administered and what actually happened.
If a seller says an NAD product “supports GLP-1,” ask it to define the claim. Does it mean a demonstrated change in hormone secretion, appetite, weight or glucose control? Those are separate propositions. A vague pathway association is not a substitute for the direct human result reported here.
The trial should also retain its ingredient identity. It studied NR. It did not compare NMN with prescription metabolic treatments, and it did not evaluate an NAD+ injection. Our ingredient guide helps prevent similar names from creating false equivalence.
How to organize related publications
This hormone analysis comes from the same forty-person research program discussed in the insulin-resistance article. It adds a different set of measurements, not a new independent cohort. [1]
When reading an evidence page, look for trial identifiers and participant descriptions as well as publication titles. Several papers can increase understanding of one experiment without increasing the number of separate experiments. That distinction is especially useful when a long bibliography is offered as the main reason to trust a product.
The result leaves a clear consumer boundary: this study does not substantiate an incretin-enhancing benefit from oral NR in the tested group. It also does not prove that every possible future intervention is ineffective; that would require a broader claim than the experiment supports.
Bring questions about appetite, blood sugar or diagnosed metabolic conditions to a qualified clinician. Use research to clarify the exact proposition being made, rather than to infer a replacement for established treatment from a familiar hormone name. The strongest feature of this paper is the directness of its negative answer to a defined mechanistic question.